Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma [2]

Annals of Oncology

Volumn 17, Issue 11, 2006, Pages 1720-1721

  Errante, Domencio ^a   Bernardi, D ^a   Bianco, A ^a   De Nardi, S ^a   Salvagno, L ^a  

^a OSPEDALE CA FONCELLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENIRAMINE; CORTICOSTEROID; PARACETAMOL; RITUXIMAB;

ADULT; B CELL LYMPHOMA; CANCER REGRESSION; CASE REPORT; CLINICAL PROTOCOL; DRUG INFUSION; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; LETTER; MALE; NONHODGKIN LYMPHOMA; PATIENT REFERRAL; PRIORITY JOURNAL; SKIN LYMPHOMA; URTICARIA;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, B-CELL; MALE; MICE; SKIN NEOPLASMS; URTICARIA;

EID: 33750589163     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl113     Document Type: Letter

References (6)

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
2. Heinzerling LM, Urbanek M, Funk JO et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-1844.
3. Winkler U, Jensen M, Manzke O et al. Cytokine-release syndrome in patients with B-cell chronic limphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217-2224.
4. van der Kolk LE, Grillo-Lopez, Baars JW et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115: 807-811.
5. Lowndes S, Darby A, Meal G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13: 1948-1950.
6. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximub treatment. Ann Oncol 2003; 14: 1792.